A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration
Latest Information Update: 10 Jul 2019
At a glance
- Drugs Volociximab (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Sponsors IVERIC bio
Most Recent Events
- 01 Oct 2014 New trial record